VBI Vaccines Inc. Share Price Toronto S.E.
Equities
VBV
CA91822J1030
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.82 CAD | -5.12% | -7.66% | -10.58% |
05-15 | Earnings Flash (VBIV) VBI VACCINES Reports Q1 Revenue $1.2M | MT |
04-16 | VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 14.48M 19.68M 1.14B | Sales 2025 * | 34.12M 46.38M 2.69B | Capitalization | 18.27M 24.83M 1.44B |
---|---|---|---|---|---|
Net income 2024 * | -42M -57.08M -3.31B | Net income 2025 * | -25M -33.98M -1.97B | EV / Sales 2024 * | 1.26 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.54 x |
P/E ratio 2024 * |
-0.47
x | P/E ratio 2025 * |
-1.29
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.01% |
1 day | -5.12% |
Managers | Title | Age | Since |
---|---|---|---|
Jeff Baxter
CEO | Chief Executive Officer | 62 | 30/04/16 |
Nell Beattie
DFI | Director of Finance/CFO | 36 | 08/07/15 |
David Anderson
CTO | Chief Tech/Sci/R&D Officer | 54 | 05/05/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vaughn Himes
BRD | Director/Board Member | 63 | 23/04/23 |
Steven Gillis
CHM | Chairman | 71 | 31/12/04 |
Jeff Baxter
CEO | Chief Executive Officer | 62 | 30/04/16 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- VBIV Stock
- VBV Stock